Cargando…

Immunogenicity of TNF-Inhibitors

Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of rheumatic diseases since their incorporation into treatment protocols two decades ago. Nevertheless, a substantial fraction of patients experiences either primary or secondary failure to TNFi due to ineffectiven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atiqi, Sadaf, Hooijberg, Femke, Loeff, Floris C., Rispens, Theo, Wolbink, Gerrit J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055461/ https://www.ncbi.nlm.nih.gov/pubmed/32174918 http://dx.doi.org/10.3389/fimmu.2020.00312

Ejemplares similares

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange
por: van Schie, Karin A., et al.
Publicado: (2016)

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
por: Krieckaert, Charlotte Louise Maria, et al.
Publicado: (2010)

What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
por: Mehta, Puja, et al.
Publicado: (2020)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands
por: Boekel, Laura, et al.
Publicado: (2023)

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
por: Boekel, Laura, et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence
por: Bendtzen, Klaus
Publicado: (2015)

Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated
por: Raadsen, Reinder, et al.
Publicado: (2023)

IgG Subclasses and Allotypes: From Structure to Effector Functions
por: Vidarsson, Gestur, et al.
Publicado: (2014)

Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases
por: Dekkers, Gillian, et al.
Publicado: (2018)

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
por: Boekel, Laura, et al.
Publicado: (2022)

Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection
por: Bendtzen, Klaus
Publicado: (2015)

Perspective of patients with autoimmune diseases on COVID-19 vaccination
por: Boekel, Laura, et al.
Publicado: (2021)

Biased anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics
por: Großerichter-Wagener, Christina, et al.
Publicado: (2020)

Ferric carboxymaltose and SARS-CoV-2 vaccination-induced immunogenicity in kidney transplant recipients with iron deficiency: The COVAC-EFFECT randomized controlled trial
por: Vinke, Joanna Sophia J., et al.
Publicado: (2023)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Liu, Xiaohang, et al.
Publicado: (2022)

Use of TNF Inhibitors in Rheumatoid Arthritis and Implications for the Periodontal Status: For the Benefit of Both?
por: Zamri, Fatima, et al.
Publicado: (2020)

Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
por: Ou, Jiayong, et al.
Publicado: (2021)

Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)
por: Nassar-Sheikh Rashid, A., et al.
Publicado: (2021)

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
por: Rivera Vargas, Thaiz, et al.
Publicado: (2019)

TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice
por: Gao, Jian, et al.
Publicado: (2022)

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
por: Jani, Meghna, et al.
Publicado: (2014)

Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization
por: Thornlow, Dana N., et al.
Publicado: (2021)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020)

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
por: Rodríguez-Martín, Eulalia, et al.
Publicado: (2020)

IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis
por: Dong, Qiang, et al.
Publicado: (2022)

BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

Immunogenicity and toxicity of AAV gene therapy
por: Ertl, Hildegund C. J.
Publicado: (2022)

Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
por: Boekel, Laura, et al.
Publicado: (2021)

Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration
por: de Vries, Fenna, et al.
Publicado: (2023)

C-tag TNF: a reporter system to study TNF shedding
por: Pinci, Francesca, et al.
Publicado: (2021)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

Optimized Protocols for In-Vitro T-Cell-Dependent and T-Cell-Independent Activation for B-Cell Differentiation Studies Using Limited Cells
por: Marsman, Casper, et al.
Publicado: (2022)

Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases
por: Eek Mariampillai, Adrian, et al.
Publicado: (2023)

The Risk of Adverse Effects of TNF-α Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis
por: He, Bei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dpg743jtlho35f97ucc8vl288h